Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
BENHEALTH BIOPHARMACEUTIC (SHENZHEN) CO., LTD. manages a portfolio in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions. This workload is distributed across 2 distinct examiners and 2 distinct art units. The presence of multiple examiners suggests that the company is pursuing several distinct lines of inquiry or different patent families simultaneously.
The busiest examiner for this company is PUTTLITZ, KARL J, who is currently responsible for 2 pending office actions. This examiner's workload is compared to the 3 total pending office actions for the company. With 2 distinct art units involved, the prosecution activity spans multiple specialized technical groups at the USPTO.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 2 | 69.2% | +18.5% |
| LU, CHENG | 1 | 53.8% | +64.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16935679 | BISPECIFIC ANTIBODY CAPABLE OF BEING COMBINED WITH IMMUNE CELLS TO ENHANCE TUMOR KILLING CAPABILITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LU, CHENG | 32d overdue |
| 17224288 | MULTI-SPECIFIC BINDING CONJUGATE, RELATED PHARMACEUTICAL COMPOSITIONS AND USE | PUTTLITZ, KARL J | — |
| 16480506 | ANTIBODY CONJUGATE, AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 2 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17224288 | MULTI-SPECIFIC BINDING CONJUGATE, RELATED PHARMACEUTICAL COMPOSITIONS AND USE | PUTTLITZ, KARL J | 1646 | DP | Final Rejection | — | Pending | Jun 02, 2021 |
| 16935679 | BISPECIFIC ANTIBODY CAPABLE OF BEING COMBINED WITH IMMUNE CELLS TO ENHANCE TUMOR KILLING CAPABILITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LU, CHENG | 1642 | §103DP | Non-Final OA | 32d overdue | Pending | Jul 22, 2020 |
| 16480506 | ANTIBODY CONJUGATE, AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION | PUTTLITZ, KARL J | 1646 | §103 | Final Rejection | — | Pending | Jul 24, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBENHEALTH BIOPHARMACEUTIC (SHENZHEN) CO., LTD. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Karl J Puttlitz has the most, with 2 of BENHEALTH BIOPHARMACEUTIC (SHENZHEN) CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
